Literature DB >> 8858954

Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine.

N Drion1, M Lemaire, J M Lefauconnier, J M Scherrmann.   

Abstract

Classically, drug penetration through the blood-brain barrier depends on the lipid solubility of the substance, except for some highly lipophilic drugs, like colchicine and vinblastine, both substrates of P-glycoprotein, a drug efflux pump present at the luminal surface of the brain capillary endothelial cells. Colchicine and vinblastine uptake into the brain was studied in the rat using the in situ brain perfusion technique and two inhibitors of P-glycoprotein, verapamil and SDZ PSC-833. When rats were pretreated with PSC-833 (10 mg/kg, intravenous bolus), colchicine and vinblastine uptake was enhanced 8.42- and 9.08-fold, respectively, in all the gray areas of the rat brain studied. The mean colchicine distribution volume was increased from 0.67 +/- 0.41 to 5.64 +/- 0.70 microliters/g and vinblastine distribution volume from 2.74 +/- 1.15 to 24.88 +/- 4.03 microliters/g. When rats were pretreated with verapamil (1 mg/kg, intravenous bolus), colchicine distribution volume was increased 3.70-fold. The increase in colchicine and vinblastine did not differ between the eight brain gray areas. PSC-833 and verapamil pretreatment had no influence on the distribution volume of either drug in the choroid plexus. Nevertheless, distribution volumes remained small, considering the highly lipophilic nature of the substances. We suggest that P-glycoprotein is either only partially inhibited (difficulty of fully saturating P-glycoprotein, especially under in vivo conditions) or not the only barrier to these two drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8858954     DOI: 10.1046/j.1471-4159.1996.67041688.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

Review 1.  Determinants of passive drug entry into the central nervous system.

Authors:  M D Habgood; D J Begley; N J Abbott
Journal:  Cell Mol Neurobiol       Date:  2000-04       Impact factor: 5.046

Review 2.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

4.  Computational prediction of CNS drug exposure based on a novel in vivo dataset.

Authors:  Christel A S Bergström; Susan A Charman; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2012-06-29       Impact factor: 4.200

5.  Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier.

Authors:  L Fenart; V Buée-Scherrer; L Descamps; C Duhem; M G Poullain; R Cecchelli; M P Dehouck
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

6.  Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

Authors:  Stephan Fellner; Björn Bauer; David S Miller; Martina Schaffrik; Martina Fankhänel; Thilo Spruss; Günther Bernhardt; Claudia Graeff; Lothar Färber; Harald Gschaidmeier; Armin Buschauer; Gert Fricker
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 7.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.

Authors:  S Cisternino; C Rousselle; C Dagenais; J M Scherrmann
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

9.  Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.

Authors:  J W Jonker; E Wagenaar; L van Deemter; R Gottschlich; H M Bender; J Dasenbrock; A H Schinkel
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

10.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Authors:  U Mayer; E Wagenaar; B Dorobek; J H Beijnen; P Borst; A H Schinkel
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.